Pulse Biosciences

PLSE

Market cap $897M

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awa.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to participate in two upcoming investor conferences. Stifel 2025 Healthcare Conference, in New York, New York. Management is scheduled to present on Thursday, November 13, 2025, at 2:40 pm ET. Piper Sandler 37th Annual Healthcare Conference, in New York, New Yor.

Pulse Biosciences, Inc. ( PLSE ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul LaViolette - President, CEO & Co-Chairman of the Board Jon Skinner - Chief Financial Officer Conference Call Participants Philip Taylor - Gilmartin Group LLC Suraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Hello, and thank you for standing by. My name is Mark, and I will be your conference operator today.

Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.16 per share a year ago.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the third quarter ended September 30, 2025. Recent Business Highlights Soft Tissue Ablation Initiated a multi-center clinical study, PRECISE-BTN, for the treatment of benign thyroid nodules (BTN) with the nPulse Vybrance perc.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the enrollment of the first patient in its NANOCLAMP AF Study for the treatment of atrial fibrillation (AF). The successful first procedure was completed at St. Helena Hospital in St. Helena, California, with the nPulse™ Cardiac Surgical System following its recent FD.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to th.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awa.

PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical study results from the nPulse™ Cardiac Surgical System first-in-human feasibility study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen, Denmark. The feasibility study is intended to assess the initial s.